CL2008000502A1 - Compuestos derivados de amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas; procedimiento de preparacion; medicamento; y uso del compuesto para el tratamiento y/o profilaxis de aldosteronismo, presion sanguinea alta, fallo cardiaco cronico, sec - Google Patents
Compuestos derivados de amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas; procedimiento de preparacion; medicamento; y uso del compuesto para el tratamiento y/o profilaxis de aldosteronismo, presion sanguinea alta, fallo cardiaco cronico, secInfo
- Publication number
- CL2008000502A1 CL2008000502A1 CL200800502A CL2008000502A CL2008000502A1 CL 2008000502 A1 CL2008000502 A1 CL 2008000502A1 CL 200800502 A CL200800502 A CL 200800502A CL 2008000502 A CL2008000502 A CL 2008000502A CL 2008000502 A1 CL2008000502 A1 CL 2008000502A1
- Authority
- CL
- Chile
- Prior art keywords
- naftiridine
- profilaxis
- amidas
- dihidro
- aldosteronism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007009494A DE102007009494A1 (de) | 2007-02-27 | 2007-02-27 | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008000502A1 true CL2008000502A1 (es) | 2008-06-13 |
Family
ID=39512753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200800502A CL2008000502A1 (es) | 2007-02-27 | 2008-02-19 | Compuestos derivados de amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas; procedimiento de preparacion; medicamento; y uso del compuesto para el tratamiento y/o profilaxis de aldosteronismo, presion sanguinea alta, fallo cardiaco cronico, sec |
Country Status (45)
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP3593802A3 (en) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
BR112014010228B1 (pt) | 2011-10-28 | 2020-09-29 | Lumena Pharmaceuticals Llc | Uso de inibidores de reciclagem de ácido biliar para o tratamento de hipercolemia e doença hepática colestática |
PL2771003T3 (pl) | 2011-10-28 | 2017-10-31 | Lumena Pharmaceuticals Llc | Inhibitory ponownego wykorzystania kwasów żółciowych do leczenia pediatrycznych cholestatycznych chorób wątroby |
CN104871026B (zh) * | 2012-12-17 | 2020-01-10 | 通用电气公司 | 靶物质的体外磁共振检测 |
RU2015139732A (ru) | 2013-03-15 | 2017-04-24 | ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи | Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни |
BR112015023646A2 (pt) | 2013-03-15 | 2017-07-18 | Lumena Pharmaceuticals Inc | inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino |
CN103193704B (zh) * | 2013-04-12 | 2016-03-09 | 四川铂瑞生物医药有限公司 | 2-羟基-4-氨基-5-甲基吡啶杂环化合物 |
AU2015282450C1 (en) | 2014-06-30 | 2018-09-20 | Astrazeneca Ab | Benzoxazinone amides as mineralocorticoid receptor modulators |
ES2828704T3 (es) | 2014-08-01 | 2021-05-27 | Bayer Pharma AG | Procedimiento para la preparación de (4S)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida y su purificación para su uso como principio activo farmacéutico |
WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
JOP20160185B1 (ar) * | 2015-08-21 | 2021-08-17 | Bayer Pharma AG | طريقة لتحضير (4s)-4-(4- سيانو-2- ميثوكسي فنيل)-5- إيثوكسي-8،2-داي ميثيل-4،1-داي هيدرو-6،1- نافثيريدين-3- كربوكساميد واسترجاع (4s)-4-(4- سيانو-2- ميثوكسي فنيل)-5- إيثوكسي-8،2- داي ميثيل-4،1- داي هيدرو-6،1- نافثيريدين-3- كربوكساميد بواسطة طرق كهروكيميائية |
RS59055B1 (sr) * | 2015-08-21 | 2019-08-30 | Bayer Pharma AG | Postupak za proizvodnju (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-karboksamida i njegovo prečišćavanje u svrhu upotrebe kao farmaceutski aktivne supstance |
JP2018523698A (ja) * | 2015-08-21 | 2018-08-23 | バイエル・ファルマ・アクティエンゲゼルシャフト | (4s)−および(4r)−4−(4−シアノ−2−メトキシフェニル)−5−エトキシ−2,8−ジメチル−1,4−ジヒドロ−1,6−ナフチリジン−3−カルボキサミドの代謝産物の調製方法およびその使用 |
EP3362095B1 (en) | 2015-10-13 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation |
WO2017093348A1 (en) | 2015-12-02 | 2017-06-08 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
CN110022871A (zh) * | 2016-10-11 | 2019-07-16 | 拜耳制药股份公司 | 包含sGC刺激物和盐皮质激素受体拮抗剂的组合产品 |
WO2018153898A1 (de) * | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten |
BR112019024984A2 (pt) | 2017-06-02 | 2020-06-23 | Syngenta Participations Ag | Derivados de oxadiazol microbicidas |
DE102017008472A1 (de) | 2017-09-08 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend PDE5 Inhibitoren und Mineralocorticoid-Rezeptor-Antagonisten |
CN109721536B (zh) * | 2017-10-27 | 2020-11-24 | 广东东阳光药业有限公司 | 苯基取代的稠合三环类化合物及其用途 |
EP3560922A1 (de) | 2018-04-24 | 2019-10-30 | Bayer Aktiengesellschaft | Verfahren zur herstellung von (4s)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carbox-amid durch racemat-spaltung mittels diastereomerer weinsäureester |
WO2019223629A1 (zh) * | 2018-05-22 | 2019-11-28 | 广东东阳光药业有限公司 | 苯基取代的二氢萘啶类化合物及其用途 |
CN110917195A (zh) * | 2018-08-20 | 2020-03-27 | 山西惠尔健生物科技有限公司 | 肌松剂阿库氯铵(Alcuronium chloride)可作为抗心律失常药物 |
AU2020221834A1 (en) | 2019-02-12 | 2021-09-02 | Mirum Pharmaceuticals, Inc. | Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency |
EP3935044B1 (de) | 2019-03-05 | 2023-04-12 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 4-amino-5-methylpyridon |
MX2021010612A (es) | 2019-03-05 | 2021-09-28 | Bayer Ag | Sintesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermediario para la sintesis del antagonista mr finerenona) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermediario 2-cloro-5-metil-4-piridinamina. |
CA3158165A1 (en) * | 2019-10-17 | 2021-04-22 | Bayer Aktiengesellschaft | Process for the preparation of (2-cyanoethyl (4s)-4-(4-cyano-2-methoxy-phenyl)-5-hydroxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridin-3-carboxylate by racemate separation by means of diastereomeric tartaric acid esters |
JP2022553224A (ja) * | 2019-10-17 | 2022-12-22 | バイエル アクチェンゲゼルシャフト | (4r,4s)-4-(4-シアノ-2-メトキシフェニル)-5-エトキシ-2,8-ジメチル-1,4-ジヒドロ-1,6-ナフチリジン-3-カルボキサミドを製造するための光化学法 |
KR20220084103A (ko) * | 2019-10-17 | 2022-06-21 | 바이엘 악티엔게젤샤프트 | 부분입체이성질체 타르타르산 에스테르를 사용한 라세미체 분해에 의한 2-시아노에틸 (4s)-4-(4-시아노-2-메톡시페닐)-5-에톡시-2,8-디메틸-1,4-디히드로-1,6-나프티리딘-3-카르복실레이트의 제조 방법 |
MX2022004480A (es) * | 2019-10-17 | 2022-05-06 | Bayer Ag | Procedimiento para preparar esteres aciloximetilicos del acido (4s)-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6- naftiridin-3-carboxilico. |
EP4118235A1 (en) | 2020-03-11 | 2023-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy |
CN115916197A (zh) | 2020-04-22 | 2023-04-04 | 拜耳公司 | 用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合 |
EP3900722A1 (en) | 2020-04-22 | 2021-10-27 | Bayer AG | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
WO2021213493A1 (zh) * | 2020-04-24 | 2021-10-28 | 东莞市东阳光新药研发有限公司 | 二氢萘啶类化合物的晶型及其用途 |
CN113549066B (zh) * | 2020-04-24 | 2023-07-21 | 年衍药业(珠海)有限公司 | 二氢萘啶类化合物的晶型及其用途 |
TW202214624A (zh) | 2020-06-16 | 2022-04-16 | 德商拜耳廠股份有限公司 | 藉由催化不對稱漢斯(hantzsch)酯還原法進行之製備(4s)-4-(4-氰基-2-甲氧基苯基)-5-乙氧基-2,8-二甲基-1,4-二氫-1,6-㖠啶-3-羧醯胺的方法 |
WO2022214206A1 (en) | 2021-04-08 | 2022-10-13 | Bayer Aktiengesellschaft | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases |
EP4373476A1 (en) * | 2021-07-21 | 2024-05-29 | Cyta Therapeutics, Inc. | Particle delivery of thyroid hormone receptor agonists and antagonists |
WO2023031277A1 (en) | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of ocular rosacea |
AU2022348784A1 (en) | 2021-09-18 | 2024-04-04 | Tuojie Biotech (Shanghai) Co., Ltd. | Substituted 1,4-dihydro-1,6-naphthyridine amide and use thereof |
CN114149427A (zh) * | 2021-12-18 | 2022-03-08 | 上海鼎雅药物化学科技有限公司 | 非奈利酮及其中间体的合成方法 |
WO2023205164A1 (en) | 2022-04-18 | 2023-10-26 | Teva Pharmaceuticals International Gmbh | Processes for the preparation of finerenone |
EP4286368A1 (de) | 2022-05-31 | 2023-12-06 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 4-formyl-3-methoxybenzonitril |
WO2024022481A1 (zh) * | 2022-07-29 | 2024-02-01 | 苏中药业集团股份有限公司 | 苯基取代的二氢萘啶类化合物及其制备与用途 |
CN116715664A (zh) * | 2023-06-12 | 2023-09-08 | 常州制药厂有限公司 | 一种非奈利酮关键中间体的制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4698341A (en) | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
DE3502831A1 (de) | 1985-01-29 | 1986-07-31 | Gödecke AG, 1000 Berlin | 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung |
DE3327650A1 (de) | 1983-07-30 | 1985-02-14 | Gödecke AG, 1000 Berlin | 1,6-naphthyridinon-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von gefaesserkrankungen |
US4760081A (en) | 1984-08-25 | 1988-07-26 | Goedecke Aktiengesellschaft | 1,6-naphthyridine derivatives useful for treating diseases of the blood vessels |
DE3431303A1 (de) | 1984-08-25 | 1986-02-27 | Goedecke Ag | 1,6-naphthyridin-derivate, verfahren zu deren herstellung und deren verwendung |
IL75987A (en) | 1984-08-25 | 1991-07-18 | Goedecke Ag | Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
WO2002010164A2 (en) | 2000-08-02 | 2002-02-07 | Abbott Laboratories | Dihydronaphthyridine- and dihydropyrrolopyridine-derivated compounds as potassium channel openers |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
DE102004012365A1 (de) | 2004-03-13 | 2005-09-29 | Bayer Healthcare Ag | Substituierte Dihydropyridine |
JP2007230869A (ja) | 2004-04-05 | 2007-09-13 | Takeda Chem Ind Ltd | アルドステロン受容体拮抗剤 |
RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
CA2589777A1 (en) | 2004-12-13 | 2006-06-22 | Irm Llc | Compounds and compositions as modulators of steroidal receptors and calcium channel activities |
CN101227857B (zh) | 2005-06-29 | 2011-10-19 | 电脑医师有限公司 | 具有导电桥的传感器组件 |
DE102005034264A1 (de) | 2005-07-22 | 2007-02-01 | Bayer Healthcare Ag | 4-Chromenonyl-1,4-dihydropyridincarbonitrile und ihre Verwendung |
DE102006026583A1 (de) * | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung |
DE102006026585A1 (de) * | 2006-06-07 | 2007-12-13 | Bayer Healthcare Aktiengesellschaft | Substituierte 4-Aryl-1,4-dihydro-1,6-naphthyridine und ihre Verwendung |
-
2007
- 2007-02-27 DE DE102007009494A patent/DE102007009494A1/de not_active Withdrawn
-
2008
- 2008-02-17 SA SA8290071A patent/SA08290071B1/ar unknown
- 2008-02-18 PA PA20088770101A patent/PA8770101A1/es unknown
- 2008-02-19 PE PE2008000351A patent/PE20090724A1/es active IP Right Grant
- 2008-02-19 SI SI200831451T patent/SI2132206T1/sl unknown
- 2008-02-19 UA UAA200909818A patent/UA102065C2/ru unknown
- 2008-02-19 UY UY0001038952A patent/UY38952A/es not_active Application Discontinuation
- 2008-02-19 BR BR122020008544A patent/BR122020008544B8/pt active IP Right Grant
- 2008-02-19 HU HUE08715849A patent/HUE026441T2/en unknown
- 2008-02-19 MY MYPI2013000708A patent/MY176873A/en unknown
- 2008-02-19 CL CL200800502A patent/CL2008000502A1/es unknown
- 2008-02-19 PL PL08715849T patent/PL2132206T3/pl unknown
- 2008-02-19 PT PT87158499T patent/PT2132206E/pt unknown
- 2008-02-19 NZ NZ579230A patent/NZ579230A/en unknown
- 2008-02-19 DK DK08715849.9T patent/DK2132206T3/en active
- 2008-02-19 CA CA2679232A patent/CA2679232C/en active Active
- 2008-02-19 UY UY0001038953A patent/UY38953A/es not_active Application Discontinuation
- 2008-02-19 EP EP08715849.9A patent/EP2132206B1/de active Active
- 2008-02-19 ES ES08715849.9T patent/ES2540803T3/es active Active
- 2008-02-19 MY MYPI20093470 patent/MY150748A/en unknown
- 2008-02-19 KR KR1020097017818A patent/KR101614164B1/ko active IP Right Grant
- 2008-02-19 MX MX2009008701A patent/MX2009008701A/es active IP Right Grant
- 2008-02-19 JP JP2009550238A patent/JP5367586B2/ja active Active
- 2008-02-19 WO PCT/EP2008/001257 patent/WO2008104306A2/de active Application Filing
- 2008-02-19 CN CN2008800063770A patent/CN101641352B/zh active Active
- 2008-02-19 US US12/526,951 patent/US8436180B2/en active Active
- 2008-02-19 BR BRPI0808098A patent/BRPI0808098B8/pt active IP Right Grant
- 2008-02-19 AU AU2008221071A patent/AU2008221071B2/en active Active
- 2008-02-19 UY UY30931A patent/UY30931A1/es active IP Right Grant
- 2008-02-25 AR ARP080100769A patent/AR065463A1/es active IP Right Grant
- 2008-02-26 TW TW102122083A patent/TWI474821B/zh active
- 2008-02-26 JO JOP/2008/0080A patent/JO3018B1/ar active
- 2008-02-26 TW TW097106529A patent/TWI415608B/zh active
-
2009
- 2009-07-23 IL IL200060A patent/IL200060A/en active IP Right Grant
- 2009-07-30 TN TNP2009000318A patent/TN2009000318A1/fr unknown
- 2009-08-13 GT GT200900230A patent/GT200900230A/es unknown
- 2009-08-14 HN HN2009001597A patent/HN2009001597A/es unknown
- 2009-08-14 EC EC2009009581A patent/ECSP099581A/es unknown
- 2009-08-14 CR CR10976A patent/CR10976A/es unknown
- 2009-08-14 DO DO2009000205A patent/DOP2009000205A/es unknown
- 2009-08-14 CU CUP2009000148A patent/CU23874B1/es active IP Right Grant
- 2009-08-18 CO CO09085903A patent/CO6220951A2/es not_active Application Discontinuation
- 2009-08-18 ZA ZA200905730A patent/ZA200905730B/xx unknown
- 2009-09-10 MA MA32211A patent/MA31245B1/fr unknown
-
2010
- 2010-06-28 HK HK10106307.3A patent/HK1140194A1/xx unknown
-
2013
- 2013-03-13 US US13/801,376 patent/US9051316B2/en active Active
- 2013-08-05 JP JP2013162179A patent/JP5752754B2/ja active Active
-
2015
- 2015-06-30 CY CY20151100566T patent/CY1116455T1/el unknown
- 2015-06-30 HR HRP20150702TT patent/HRP20150702T1/hr unknown
-
2022
- 2022-05-03 HU HUS2200015C patent/HUS2200015I1/hu unknown
- 2022-05-05 FR FR22C1017C patent/FR22C1017I2/fr active Active
- 2022-06-21 LT LTPA2022512C patent/LTPA2022512I1/lt unknown
- 2022-08-11 NL NL301192C patent/NL301192I2/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008000502A1 (es) | Compuestos derivados de amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas; procedimiento de preparacion; medicamento; y uso del compuesto para el tratamiento y/o profilaxis de aldosteronismo, presion sanguinea alta, fallo cardiaco cronico, sec | |
CL2008000377A1 (es) | Compuestos derivados de ciclos fusionados sustituidos; agente farmaceutico que comprende a dichos compuestos; y uso para la prevencion o tratamiento de la diabetes. | |
CL2012002356A1 (es) | Compuestos heterociclicos acidos derivados de ariltriazolonas ligadas a bisarilo, inhibidores de receptores de vasopresina v1a y v2; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar y/o prevenir insuficiencia cardiaca aguda y cronica, hiponatremia, entre otras. | |
BR112015003109A2 (pt) | Composto, composição, uso de um composto, e, métodos para tratar ou prevenir um distúrbio, condição ou doença e para tratar diabetes mellitus tipo 2. | |
CL2014000504A1 (es) | Compuestos derivados de pirimidinas condensadas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de la insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
CL2008000059A1 (es) | Compuestos derivados de espiropiperidina-glicinamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hipertension, dismenorrea, fallo cardiaco cronico, ansiedad, t | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
CL2007002610A1 (es) | Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras. | |
CL2013001600A1 (es) | Compuestos derivados de acidos 1-bencilcicloalquilcarboxilicos sustituidos; procedimiento de preparacion de dichos compuestos; medicamento que los contiene; y su uso para el tratamiento y/o la prevencion de insuficiencia cardiaca, angina pectoris, hipertonia, afecciones tromboembolicas, insuficiencia renal, entre otras. | |
CL2014001779A1 (es) | Compuestos derivados de pirimidinas y triazinas fusionadas sustituidas; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento y/o prevencion de insuficiencia cardiaca, angina de pecho, hipertension, entre otras enfermedades. | |
CL2007003495A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer. | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
CL2013002414A1 (es) | Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension. | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
CL2007003803A1 (es) | Compuestos derivados de sulfonamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer, dislipidemia, diabetes, obesidad, infeccion. | |
CL2012000754A1 (es) | Compuestos derivados de benzoxazepina condensadas con pirazolilo o imidazolilo, inhibidores de la actividad de la quinasa pi3; composicion farmaceutica que comprende un compuesto; y su uso en la preparacion de medicamentos para el tratamiento del cancer. | |
CL2008001076A1 (es) | Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer. | |
BRPI0911203A2 (pt) | peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo. | |
BR112015020209A2 (pt) | uso de linagliptina em terapia antidiabética de proteção cardíaca e renal | |
BRPI0814957A2 (pt) | Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto. | |
BRPI0915105A2 (pt) | composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer | |
MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
CL2008000254A1 (es) | Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer. |